[HTML][HTML] New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials

H Jin, S Qin, J He, J Xiao, Q Li, Y Mao… - International Journal of …, 2022 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is one of the most lethal tumors in China and worldwide,
although first-line therapies for HCC, such as atezolizumab and bevacizumab, have been …

Reinvigorating exhausted CD8+ cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy

MA Hossain, G Liu, B Dai, Y Si, Q Yang… - Medicinal Research …, 2021 - Wiley Online Library
Immunotherapy has revolutionized the treatment of cancer in recent years and achieved
overall success and long‐term clinical benefit in patients with a wide variety of cancer types …

TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory

I Ausejo-Mauleon, S Labiano, D de la Nava… - Cancer Cell, 2023 - cell.com
Diffuse intrinsic pontine glioma (DIPG) is an aggressive brain stem tumor and the leading
cause of pediatric cancer-related death. To date, these tumors remain incurable …

[HTML][HTML] Tim-3 aggravates podocyte injury in diabetic nephropathy by promoting macrophage activation via the NF-κB/TNF-α pathway

H Yang, T Xie, D Li, X Du, T Wang, C Li, X Song… - Molecular …, 2019 - Elsevier
Objective Macrophage-mediated inflammation plays a significant role in the development
and progression of diabetic nephropathy (DN). However, the underlying mechanisms …

IL‐6 promotes metastasis of non‐small‐cell lung cancer by up‐regulating TIM‐4 via NF‐κB

W Liu, H Wang, F Bai, L Ding, Y Huang, C Lu… - Cell …, 2020 - Wiley Online Library
Abstract Objectives Interleukin‐6 (IL‐6) is critical for the development of non‐small‐cell lung
cancer (NSCLC). Recently, we identified T‐cell immunoglobulin domain and mucin domain …

CircSOD2 induced epigenetic alteration drives hepatocellular carcinoma progression through activating JAK2/STAT3 signaling pathway

Z Zhao, J Song, B Tang, S Fang, D Zhang… - Journal of Experimental …, 2020 - Springer
Background Emerging evidence suggests that circular RNAs play critical roles in disease
development especially in cancers. Previous genome-wide RNA-seq studies found that a …

Tim-3 expression and its role in hepatocellular carcinoma

F Liu, Y Liu, Z Chen - Journal of hematology & oncology, 2018 - Springer
Hepatocellular carcinoma (HCC) is one of the most common tumors in the world, and its
mortality is still on the rise. Limited treatments and low chemotherapy sensitivity of HCC …

TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors

N Sauer, N Janicka, W Szlasa, B Skinderowicz… - Cancer Immunology …, 2023 - Springer
T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) expression has been
a trending topic in recent years due to its differential expression in a wide range of …

Immune co-inhibitory receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in medullary thyroid cancers: a large cohort study

X Shi, CW Li, LC Tan, SS Wen, T Liao… - The Journal of …, 2021 - academic.oup.com
Context Programmed cell death protein-1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-
4), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), lymphocyte activation …

Cytokines, breast cancer stem cells (BCSCs) and chemoresistance

W Chen, Y Qin, S Liu - Clinical and translational medicine, 2018 - Springer
Chemotherapy resistance of breast cancer poses a great challenge to the survival of
patients. During breast cancer treatment, the development of intrinsic and acquired drug …